These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 39127062

  • 1. Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.
    Williams LJ, Kunkler IH, Taylor KJ, Dunlop J, Piper T, Caldwell J, Jack W, Loane JF, Elder K, Bartlett JMS, Dixon JM, Cameron DA.
    Lancet Oncol; 2024 Sep; 25(9):1213-1221. PubMed ID: 39127062
    [Abstract] [Full Text] [Related]

  • 2. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group.
    Forrest AP, Stewart HJ, Everington D, Prescott RJ, McArdle CS, Harnett AN, Smith DC, George WD.
    Lancet; 1996 Sep 14; 348(9029):708-13. PubMed ID: 8806289
    [Abstract] [Full Text] [Related]

  • 3. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
    Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, PRIME II investigators.
    Lancet Oncol; 2015 Mar 14; 16(3):266-73. PubMed ID: 25637340
    [Abstract] [Full Text] [Related]

  • 4. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
    Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM, TACT2 Investigators.
    Lancet Oncol; 2017 Jul 14; 18(7):929-945. PubMed ID: 28600210
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
    Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R, O'Reilly S, Bowman A, Ritchie DM, Goodman A, Hickish T, McAdam K, Cameron D, Dodwell D, Rea DW, Caldas C, Provenzano E, Abraham JE, Canney P, Crown JP, Kennedy MJ, Coleman R, Leonard RC, Carmichael JA, Wardley AM, Poole CJ, tAnGo trial collaborators.
    Lancet Oncol; 2017 Jun 14; 18(6):755-769. PubMed ID: 28479233
    [Abstract] [Full Text] [Related]

  • 7. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
    Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Bloomfield DJ, Chan C, Cleator S, Coles CE, Donovan E, Fleming H, Glynn D, Goodman A, Griffin S, Hopwood P, Kirby AM, Kirwan CC, Nabi Z, Patel J, Sawyer E, Somaiah N, Syndikus I, Venables K, Yarnold JR, Bliss JM, FAST-Forward Trial Management Group.
    Health Technol Assess; 2023 Nov 14; 27(25):1-176. PubMed ID: 37991196
    [Abstract] [Full Text] [Related]

  • 8. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM, Ciurlionis L, Chan C, Donovan EM, Emson MA, Harnett AN, Haviland JS, Hopwood P, Jefford ML, Kaggwa R, Sawyer EJ, Syndikus I, Tsang YM, Wheatley DA, Wilcox M, Yarnold JR, Bliss JM, IMPORT Trialists.
    Lancet; 2017 Sep 09; 390(10099):1048-1060. PubMed ID: 28779963
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
    Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran WJ, Bryant JL, Wolmark N.
    Lancet; 2019 Dec 14; 394(10215):2155-2164. PubMed ID: 31813636
    [Abstract] [Full Text] [Related]

  • 11. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
    Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Martín M, Nortier JW, Paterson AH, Rimawi MF, Cañada JM, Thürlimann B, Murray E, Mamounas EP, Geyer CE, Price KN, Coates AS, Gelber RD, Rastogi P, Wolmark N, Wapnir IL, CALOR investigators.
    Lancet Oncol; 2014 Feb 14; 15(2):156-63. PubMed ID: 24439313
    [Abstract] [Full Text] [Related]

  • 12. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial.
    Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, Luini A, Veronesi P, Galimberti V, Zurrida S, Leonardi MC, Lazzari R, Cattani F, Gentilini O, Intra M, Caldarella P, Ballardini B.
    Lancet Oncol; 2013 Dec 14; 14(13):1269-77. PubMed ID: 24225155
    [Abstract] [Full Text] [Related]

  • 13. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
    King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH, BIG 3-07/TROG 07.01 trial investigators.
    Lancet Oncol; 2020 May 14; 21(5):685-698. PubMed ID: 32203696
    [Abstract] [Full Text] [Related]

  • 14. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
    Bedognetti D, Sertoli MR, Pronzato P, Del Mastro L, Venturini M, Taveggia P, Zanardi E, Siffredi G, Pastorino S, Queirolo P, Gardin G, Wang E, Monzeglio C, Boccardo F, Bruzzi P.
    J Natl Cancer Inst; 2011 Oct 19; 103(20):1529-39. PubMed ID: 21921285
    [Abstract] [Full Text] [Related]

  • 15. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
    Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B, Rodenhuis C, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan D, Dubois JB, Remouchamps V, Mirimanoff RO, Collette S, Collette L, European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups.
    Lancet Oncol; 2015 Jan 19; 16(1):47-56. PubMed ID: 25500422
    [Abstract] [Full Text] [Related]

  • 16. The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.
    Fowble B, Hanlon AL, Patchefsky A, Freedman G, Hoffman JP, Sigurdson ER, Goldstein LJ.
    Int J Radiat Oncol Biol Phys; 1998 Aug 01; 42(1):105-15. PubMed ID: 9747827
    [Abstract] [Full Text] [Related]

  • 17. Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group.
    Wallgren A, Bernier J, Gelber RD, Goldhirsch A, Roncadin M, Joseph D, Castiglione-Gertsch M.
    Int J Radiat Oncol Biol Phys; 1996 Jul 01; 35(4):649-59. PubMed ID: 8690630
    [Abstract] [Full Text] [Related]

  • 18. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
    Lancet; 1996 Jul 01; 365(9472):1687-717. PubMed ID: 15894097
    [Abstract] [Full Text] [Related]

  • 19. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
    Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, Chan C, Churn M, Cleator S, Coles CE, Goodman A, Harnett A, Hopwood P, Kirby AM, Kirwan CC, Morris C, Nabi Z, Sawyer E, Somaiah N, Stones L, Syndikus I, Bliss JM, Yarnold JR, FAST-Forward Trial Management Group.
    Lancet; 2020 May 23; 395(10237):1613-1626. PubMed ID: 32580883
    [Abstract] [Full Text] [Related]

  • 20. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
    Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF, Breast Cancer Intergroup of North America.
    Lancet Oncol; 2010 Jan 23; 11(1):55-65. PubMed ID: 20005174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.